Why Fast-Cycling Skin Cells Decrease With Age

Key Takeaways

• Fibulin‑5 deficiency accelerates skin thinning and loss of fast‑cycling cells.
• Fast‑cycling epidermal stem cells decline with age, linked to ECM changes.
• YAP signaling reduction mediates loss of SLC1A3‑positive cells.
• Verteporfin inhibition of YAP reproduces aging phenotype in mouse skin.
• Restoring fibulin‑5 boosts SLC1A3 expression, suggesting therapeutic potential.

Pulse Analysis

The epidermis relies on two stem‑cell pools: slow‑cycling cells marked by DLX1 and fast‑cycling cells expressing SLC1A3. While the former maintain baseline turnover, the latter drive rapid regeneration and are especially vulnerable to age‑related extracellular matrix (ECM) alterations. Recent work highlights fibulin‑7’s role in preserving this heterogeneity, prompting investigators to examine its close relative, fibulin‑5, which declines with chronological aging and ultraviolet exposure.

In a mouse model engineered to lack fibulin‑5, researchers observed hallmark signs of accelerated skin aging: looser, thinner dermis, pigment changes, and reduced body weight. By twelve months, the regions housing fast‑cycling cells were markedly diminished, accompanied by down‑regulation of genes governing replication, adhesion, and collagen synthesis, while inflammatory pathways rose. Crucially, integrin β3 and its partner nectin‑3 were suppressed, mirroring natural aging, and YAP—a key mechanotransduction effector—was reduced across knockout, aged wild‑type, and human patient samples. Pharmacologic YAP blockade with verteporfin recapitulated the cell‑loss phenotype, underscoring YAP’s central role.

These insights suggest that restoring fibulin‑5 or enhancing YAP activity could rebalance epidermal stem‑cell populations and mitigate skin aging. However, the study stopped short of in‑vivo fibulin‑5 supplementation or YAP activation trials, leaving efficacy and safety unanswered. Future research must address delivery mechanisms, dosage, and potential off‑target effects before translating these findings into cosmetic or therapeutic products. If successful, such strategies could offer a biologically grounded alternative to existing anti‑aging creams, targeting the root cellular mechanisms rather than superficial symptoms.